These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18385750)

  • 1. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
    Quintás-Cardama A; Tong W; Kantarjian H; Thomas D; Ravandi F; Kornblau S; Manshouri T; Cortes JE; Garcia-Manero G; Verstovsek S
    Leukemia; 2008 May; 22(5):965-70. PubMed ID: 18385750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
    Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
    Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
    Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
    Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
    Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
    Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
    Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.